Immunocore Holdings stock gains on Q2 2026 revenue growth

Published on 09/03/2026 at 08:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immunocore Holdings stock is trading around its recent highs as Q2 2026 revenue rose by double digits, even though earnings missed expectations.

IMCR, GB00BL963Z95, Illustration mit AI erstellt.

Immunocore Holdings plc (ISIN GB00BL963Z95) stock closed at 37.37 US dollars on Nasdaq on September 2, 2026, valuing the biotechnology group at about 1.925 billion US dollars according to market data from Yahoo Finance.

Q2 2026 figures show solid top-line growth

According to data compiled by Yahoo Finance, Immunocore generated revenue of 115.93 million US dollars in the second quarter of fiscal year 2026, an increase of 18.3 percent compared with the prior-year quarter.

The same overview shows that Q2 FY26 earnings came in at a loss of 808,000 US dollars, corresponding to an earnings per share of minus 0.02 US dollars versus a consensus estimate of plus 0.02 US dollars for the quarter.

Profitability metrics remain in focus for investors

For the twelve months trailing the end of Q2 FY26, Yahoo Finance reports revenue of 430.78 million US dollars and net income attributable to common shareholders of minus 18.07 million US dollars, resulting in a profit margin of minus 4.20 percent on a trailing-twelve-month basis.

The same data set indicates a return on assets of minus 0.16 percent and a return on equity of minus 4.47 percent, underlining that Immunocore is still investing heavily in its pipeline relative to current profitability.

Go deeper

More background on Immunocore Holdings

Investors can explore additional news and regulatory filings on Immunocore Holdings to better understand the company's long-term strategy and risk profile.

Immunocore GB00BL963Z95 news overview Investor Relations

Pipeline built around Kimmtrak in oncology

Immunocore's commercial portfolio is led by its T cell receptor therapy Kimmtrak, an immunotherapy used to treat metastatic uveal melanoma and positioned as a key growth driver in oncology.

Stock price level for Immunocore Holdings

Based on the closing price of 37.37 US dollars on September 2, 2026 on Nasdaq, Immunocore Holdings stock reflects investor expectations of continued revenue growth in 2026 while the company works on improving margins over time.